How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

被引：0
|
作者：
Zheng, Lucy [1 ]
Zheng, X. Long [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd,Delp 5016, Kansas City, KS 66160 USA
来源：
ANNALS OF BLOOD | 2023年 / 8卷
关键词：
PLASMA-EXCHANGE; REFRACTORINESS; MORTALITY; ADAMTS13;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience
    Taylor, Alice
    Keogh, Louisa
    Dickens, Emmy
    Dutt, Tina
    Grainger, John
    Gregory, Rennick
    Mapplebeck, Claire
    Richards, Michael
    Stokley, Simone
    Salta, Styliani
    Taylor, Thomas
    Scully, Marie
    BLOOD ADVANCES, 2024, 8 (17) : 4563 - 4567
  • [32] Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura
    Sargentini-Maier, Maria Laura
    De Decker, Philip
    Tersteeg, Claudia
    Canvin, Jan
    Callewaert, Filip
    De Winter, Hilde
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (06) : 537 - 545
  • [33] Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
    Rodgers, George M.
    Berndt, Misa
    Fonteno, Megan
    Gilreath, Jeffrey A.
    JOURNAL OF BLOOD MEDICINE, 2023, 14 : 209 - 211
  • [34] More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
    Picod, Adrien
    Benhamou, Ygal
    Bouzid, Raida
    Veyradier, Agnes
    Coppo, Paul
    BLOOD ADVANCES, 2023, 7 (12) : 2678 - 2680
  • [35] Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
    Hanlon, Ashley
    Metjian, Ara
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [36] Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
    Sukumar, Senthil
    George, James N.
    Cataland, Spero R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : E76 - E77
  • [37] Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
    Goshua, George
    Sinha, Pranay
    Hendrickson, Jeanne E.
    Tormey, Christopher A.
    Bendapudi, Pavan
    Lee, Alfred Ian
    BLOOD, 2020, 136
  • [38] Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura
    Bhoopalan, Senthil Velan
    Hankins, Jane
    George, James
    Ryder, Alex
    Onder, Ali Mirza
    Puri, Latika
    PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
  • [39] Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
    Goshua, George
    Sinha, Pranay
    Hendrickson, Jeanne E.
    Tormey, Christopher
    Bendapudi, Pavan K.
    Lee, Alfred Ian
    BLOOD, 2021, 137 (07) : 969 - 976
  • [40] USE OF CAPLACIZUMAB IN PEDIATRIC THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS
    Graciaa, Sara
    Sidonio, Robert
    Zerra, Patricia
    Rollins, Margo
    Briones, Michael
    Chonat, Satheesh
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S139 - S139
12345